M2Bio Sciences, Inc | WUHN on OTC
Who are M2Bio Sciences ?
M2Bio Sciences | WUHN through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx and Medspresso brands. In addition, its new established division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer’s and Parkinson’s
M2Bio Sciences | WUHN is one of the only companies in the world to have already carried out an in vitro / in vivo study with psilocybin in animals and is currently in Pre-enrolment Patient- screening for Phase 1 Human trial
- First in market to initiate clinical trial with psilocybin for treatment of alcoholism as well as its effects to cardiovascular tissue.
- Established distribution channels in the US, Canada and Africa.
- Early stage entry into cannabinoid and psilocybin company first round of financing – enormous upside.
- Researching undiscovered properties of cannabinoids for indications & treatment of inflammatory diseases.
- Lesotho manufacturing – independent extraction & manufacturing of medicinal grade cannabinoids for the world market.
Acquisitions, divisions and strategic partnership
In recent months, M2Bio Sciences | WUHN has carried out numerous acquisitions and partnerships.
Products to come
M2Bio Sciences Inc | WUHN is preparing to put on the market a series of products based on CBD and Mushroom.
One of the most undervalued psychedelic companies on the market
M2Bio Sciences Inc | WUHN has 48 Millions shares on the market, therefore 27 Millions restricted and 14 Millions held in DTC which leaves a float of approximately 7 Millions shares. (According to OTC website)
For further information:
Sign up for MORE news updates !
This article is written and published by The Cannabis Stock
Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies
The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.
Disclosure : Wuhan General group inc (M2Bio Sciences Inc) is clients of The Cannabis Stock.